Stramsen Biotech develops plant-based medicines using a proprietary medicinal plant database and a team of experienced scientists. The company reports a robust pipeline of 33 drug candidates at various stages of development. Stramsen plans to accelerate clinical development and pursue multiple IND submissions with the FDA. Management intends to expand globally, recruit seasoned management and scientific teams, and establish a Scientific Advisory Board. The company is preparing for a prospectus submission and ultimately to pursue an initial public offering to enhance its financial position and market visibility. A recent financing commitment is positioned to fund these growth and development priorities.

Total raised

$25M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2025